English
简体中文
Total: £ 56.28
Published Date: 2026-03-06 | Pages: 119 | Tables: 120 | Pharma & Healthcare
The global Onychomycosis (Tinea Unguium) Drug market was valued at US$ 3869 million in 2025 and is anticipated to reach US$ 5710 million by 2032, at a CAGR of 5.8% from 2026 to 2032.
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.
North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.
In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.
This report delivers a comprehensive overview of the global Onychomycosis (Tinea Unguium) Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Onychomycosis (Tinea Unguium) Drug. The Onychomycosis (Tinea Unguium) Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Onychomycosis (Tinea Unguium) Drug market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Onychomycosis (Tinea Unguium) Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg
Segment by Type
Oral Medication
External Medicine
Segment by Application
Age under 18
Age 18-50
Age above 50
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Onychomycosis (Tinea Unguium) Drug companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Oral Medication
1.2.3 External Medicine
1.3 Market by Application
1.3.1 Global Onychomycosis (Tinea Unguium) Drug Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Age under 18
1.3.3 Age 18-50
1.3.4 Age above 50
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Onychomycosis (Tinea Unguium) Drug Market Perspective (2021–2032)
2.2 Global Onychomycosis (Tinea Unguium) Drug Growth Trends by Region
2.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Onychomycosis (Tinea Unguium) Drug Historic Market Size by Region (2021–2026)
2.2.3 Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (2027–2032)
2.3 Onychomycosis (Tinea Unguium) Drug Market Dynamics
2.3.1 Onychomycosis (Tinea Unguium) Drug Industry Trends
2.3.2 Onychomycosis (Tinea Unguium) Drug Market Drivers
2.3.3 Onychomycosis (Tinea Unguium) Drug Market Challenges
2.3.4 Onychomycosis (Tinea Unguium) Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue
3.1.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue (2021–2026)
3.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Players (2021–2026)
3.2 Global Top Onychomycosis (Tinea Unguium) Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Onychomycosis (Tinea Unguium) Drug Revenue
3.4 Global Onychomycosis (Tinea Unguium) Drug Market Concentration Ratio
3.4.1 Global Onychomycosis (Tinea Unguium) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Onychomycosis (Tinea Unguium) Drug Revenue in 2025
3.5 Global Key Players of Onychomycosis (Tinea Unguium) Drug Head Offices and Areas Served
3.6 Global Key Players of Onychomycosis (Tinea Unguium) Drug, Products and Applications
3.7 Global Key Players of Onychomycosis (Tinea Unguium) Drug, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Type
4.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Type (2021–2026)
4.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (2027–2032)
5 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Application
5.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Application (2021–2026)
5.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Onychomycosis (Tinea Unguium) Drug Market Size (2021–2032)
6.2 North America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021–2026)
6.4 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Onychomycosis (Tinea Unguium) Drug Market Size (2021–2032)
7.2 Europe Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021–2026)
7.4 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size (2021–2032)
8.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (2021–2026)
8.4 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Onychomycosis (Tinea Unguium) Drug Market Size (2021–2032)
9.2 Latin America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021–2026)
9.4 Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size (2021–2032)
10.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021–2026)
10.4 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Introduction
11.1.4 Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.1.5 Pfizer Recent Development
11.2 Yangtze River
11.2.1 Yangtze River Company Details
11.2.2 Yangtze River Business Overview
11.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Introduction
11.2.4 Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.2.5 Yangtze River Recent Development
11.3 Torrent Pharma
11.3.1 Torrent Pharma Company Details
11.3.2 Torrent Pharma Business Overview
11.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Introduction
11.3.4 Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.3.5 Torrent Pharma Recent Development
11.4 J&J
11.4.1 J&J Company Details
11.4.2 J&J Business Overview
11.4.3 J&J Onychomycosis (Tinea Unguium) Drug Introduction
11.4.4 J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.4.5 J&J Recent Development
11.5 Chengdu Brilliant
11.5.1 Chengdu Brilliant Company Details
11.5.2 Chengdu Brilliant Business Overview
11.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Introduction
11.5.4 Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.5.5 Chengdu Brilliant Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Introduction
11.6.4 Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.6.5 Novartis Recent Development
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Details
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Introduction
11.7.4 Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.7.5 Qilu Pharmaceutical Recent Development
11.8 Xiuzheng Pharmaceutical
11.8.1 Xiuzheng Pharmaceutical Company Details
11.8.2 Xiuzheng Pharmaceutical Business Overview
11.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Introduction
11.8.4 Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.8.5 Xiuzheng Pharmaceutical Recent Development
11.9 Hubei Hengan
11.9.1 Hubei Hengan Company Details
11.9.2 Hubei Hengan Business Overview
11.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Introduction
11.9.4 Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.9.5 Hubei Hengan Recent Development
11.10 TARO
11.10.1 TARO Company Details
11.10.2 TARO Business Overview
11.10.3 TARO Onychomycosis (Tinea Unguium) Drug Introduction
11.10.4 TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.10.5 TARO Recent Development
11.11 Perrigo
11.11.1 Perrigo Company Details
11.11.2 Perrigo Business Overview
11.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Introduction
11.11.4 Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.11.5 Perrigo Recent Development
11.12 Galderma pharm
11.12.1 Galderma pharm Company Details
11.12.2 Galderma pharm Business Overview
11.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Introduction
11.12.4 Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.12.5 Galderma pharm Recent Development
11.13 Zhejiang Deyer
11.13.1 Zhejiang Deyer Company Details
11.13.2 Zhejiang Deyer Business Overview
11.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Introduction
11.13.4 Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.13.5 Zhejiang Deyer Recent Development
11.14 Valeant Pharma
11.14.1 Valeant Pharma Company Details
11.14.2 Valeant Pharma Business Overview
11.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Introduction
11.14.4 Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.14.5 Valeant Pharma Recent Development
11.15 Moberg
11.15.1 Moberg Company Details
11.15.2 Moberg Business Overview
11.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Introduction
11.15.4 Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
11.15.5 Moberg Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Oral Medication
Table 3. Key Players of External Medicine
Table 4. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (US$ Million), 2021–2026
Table 7. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2021–2026)
Table 8. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2027–2032)
Table 10. Onychomycosis (Tinea Unguium) Drug Market Trends
Table 11. Onychomycosis (Tinea Unguium) Drug Market Drivers
Table 12. Onychomycosis (Tinea Unguium) Drug Market Challenges
Table 13. Onychomycosis (Tinea Unguium) Drug Market Restraints
Table 14. Global Onychomycosis (Tinea Unguium) Drug Revenue by Players (US$ Million), 2021–2026
Table 15. Global Onychomycosis (Tinea Unguium) Drug Market Share by Players (2021–2026)
Table 16. Global Top Onychomycosis (Tinea Unguium) Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Onychomycosis (Tinea Unguium) Drug Revenue, 2025
Table 17. Ranking of Global Top Onychomycosis (Tinea Unguium) Drug Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Onychomycosis (Tinea Unguium) Drug Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Headquarters and Area Served
Table 20. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Products and Applications
Table 21. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Onychomycosis (Tinea Unguium) Drug Market Size by Type (US$ Million), 2021–2026
Table 24. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2021–2026)
Table 25. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2027–2032)
Table 27. Global Onychomycosis (Tinea Unguium) Drug Market Size by Application (US$ Million), 2021–2026
Table 28. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2021–2026)
Table 29. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2027–2032)
Table 31. North America Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2021–2026
Table 33. North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (US$ Million), 2027–2032
Table 46. Pfizer Company Details
Table 47. Pfizer Business Overview
Table 48. Pfizer Onychomycosis (Tinea Unguium) Drug Product
Table 49. Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 50. Pfizer Recent Development
Table 51. Yangtze River Company Details
Table 52. Yangtze River Business Overview
Table 53. Yangtze River Onychomycosis (Tinea Unguium) Drug Product
Table 54. Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 55. Yangtze River Recent Development
Table 56. Torrent Pharma Company Details
Table 57. Torrent Pharma Business Overview
Table 58. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product
Table 59. Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 60. Torrent Pharma Recent Development
Table 61. J&J Company Details
Table 62. J&J Business Overview
Table 63. J&J Onychomycosis (Tinea Unguium) Drug Product
Table 64. J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 65. J&J Recent Development
Table 66. Chengdu Brilliant Company Details
Table 67. Chengdu Brilliant Business Overview
Table 68. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product
Table 69. Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 70. Chengdu Brilliant Recent Development
Table 71. Novartis Company Details
Table 72. Novartis Business Overview
Table 73. Novartis Onychomycosis (Tinea Unguium) Drug Product
Table 74. Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 75. Novartis Recent Development
Table 76. Qilu Pharmaceutical Company Details
Table 77. Qilu Pharmaceutical Business Overview
Table 78. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product
Table 79. Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 80. Qilu Pharmaceutical Recent Development
Table 81. Xiuzheng Pharmaceutical Company Details
Table 82. Xiuzheng Pharmaceutical Business Overview
Table 83. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product
Table 84. Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 85. Xiuzheng Pharmaceutical Recent Development
Table 86. Hubei Hengan Company Details
Table 87. Hubei Hengan Business Overview
Table 88. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product
Table 89. Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 90. Hubei Hengan Recent Development
Table 91. TARO Company Details
Table 92. TARO Business Overview
Table 93. TARO Onychomycosis (Tinea Unguium) Drug Product
Table 94. TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 95. TARO Recent Development
Table 96. Perrigo Company Details
Table 97. Perrigo Business Overview
Table 98. Perrigo Onychomycosis (Tinea Unguium) Drug Product
Table 99. Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 100. Perrigo Recent Development
Table 101. Galderma pharm Company Details
Table 102. Galderma pharm Business Overview
Table 103. Galderma pharm Onychomycosis (Tinea Unguium) Drug Product
Table 104. Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 105. Galderma pharm Recent Development
Table 106. Zhejiang Deyer Company Details
Table 107. Zhejiang Deyer Business Overview
Table 108. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product
Table 109. Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 110. Zhejiang Deyer Recent Development
Table 111. Valeant Pharma Company Details
Table 112. Valeant Pharma Business Overview
Table 113. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product
Table 114. Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 115. Valeant Pharma Recent Development
Table 116. Moberg Company Details
Table 117. Moberg Business Overview
Table 118. Moberg Onychomycosis (Tinea Unguium) Drug Product
Table 119. Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (US$ Million), 2021–2026
Table 120. Moberg Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
Table 124. Authors List of This Report
List of Figures
Figure 1. Onychomycosis (Tinea Unguium) Drug Picture
Figure 2. Global Onychomycosis (Tinea Unguium) Drug Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Onychomycosis (Tinea Unguium) Drug Market Share by Type: 2025 vs 2032
Figure 4. Oral Medication Features
Figure 5. External Medicine Features
Figure 6. Global Onychomycosis (Tinea Unguium) Drug Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Onychomycosis (Tinea Unguium) Drug Market Share by Application: 2025 vs 2032
Figure 8. Age under 18 Case Studies
Figure 9. Age 18-50 Case Studies
Figure 10. Age above 50 Case Studies
Figure 11. Onychomycosis (Tinea Unguium) Drug Report Years Considered
Figure 12. Global Onychomycosis (Tinea Unguium) Drug Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 13. Global Onychomycosis (Tinea Unguium) Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region: 2025 vs 2032
Figure 15. Global Onychomycosis (Tinea Unguium) Drug Market Share by Players in 2025
Figure 16. Global Onychomycosis (Tinea Unguium) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Onychomycosis (Tinea Unguium) Drug Revenue in 2025
Figure 18. North America Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 19. North America Onychomycosis (Tinea Unguium) Drug Market Share by Country (2021–2032)
Figure 20. United States Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Canada Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Onychomycosis (Tinea Unguium) Drug Market Share by Country (2021–2032)
Figure 24. Germany Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. France Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. U.K. Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Italy Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Russia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Ireland Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Share by Region (2021–2032)
Figure 32. China Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Japan Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. South Korea Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Southeast Asia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. India Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Australia & New Zealand Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Onychomycosis (Tinea Unguium) Drug Market Share by Country (2021–2032)
Figure 40. Mexico Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Brazil Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Share by Country (2021–2032)
Figure 44. Israel Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. UAE Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Pfizer Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 48. Yangtze River Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 49. Torrent Pharma Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 50. J&J Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 51. Chengdu Brilliant Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 52. Novartis Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 53. Qilu Pharmaceutical Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 54. Xiuzheng Pharmaceutical Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 55. Hubei Hengan Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 56. TARO Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 57. Perrigo Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 58. Galderma pharm Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 59. Zhejiang Deyer Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 60. Valeant Pharma Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 61. Moberg Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2021–2026)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
